dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Väljaminev kiriAvalik

Otsus

Sotsiaalministeerium · 30. august 2020
Viit
1.1-12/662
Registreeritud
30. august 2020
Dokumendi liik
Väljaminev kiri
Adressaat
Tartu Ülikool
Saabumis/saatmisviis
Outlook
Funktsioon
1.1 Juhtimine, arendus ja planeerimine
Sari
1.1-12 Ministeeriumi moodustatud komisjonide ja töögruppide tegevuse korraldamine (Arhiiviväärtuslik)
Toimik
1.1-12
Vastutaja
Ingrid Ots-Vaik (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Tervisesüsteemi arendamise osakond)

Failid

  • 📎7.EBINiotsus-vanemaealistedepressioon.asice218 KB

Sisu (failidest)

EESTI BIOEETIKA JA INIMUURINGUTE NÕUKOGU OTSUS 30. august 20 20 nr 1.1-12/662 Nõukogu koosseisus: Esimees: Liina Vahter Tallinna Ülikool Aseesimees: Aime Keis Tartu Ülikooli inimuuringute eetika komitee Teadussekretär: Aive Pevkur Tallinna Tehnikaülikool Liikmed: Kristi Rüütel Tervise Arengu Instituudi inimuuringute eetikakomitee Irja Lutsar Tartu Ülikool Kärt Salumaa-Lepik Tallinna Tehnikaülikool Meego Remmel Eesti Kirikute Nõukogu Agne Velthut-Meikas Tallinna Tehnikaülikool Merike Sisask Tallinna Ülikool Ingeri Luik-Tamme TGS Baltic Advokaadibüroo Pärt Peterson Tartu Ülikool Kristjan Kask Tallinna Ülikool Arutas 11 . augustil 20 20 .a v astutav a uurija Kelli Lehto , Tartu Ülikooli peremeditsiini ja rahvatervishoiu instituut uuringu „ Individuaalsete geeniandmete rakendamine depressiooni ja dementsuse diagnostikas vanemaealistel “ jätkutaotlust, millega soovitakse täiendada uuringumeeskonda järgmiselt : Ees- ja perekonnanimi: Triinu Ojalo Teaduslik kraad: BA psühholoogia Amet: TÜ psühholoogia instituudi magistrant Juhendaja: Kelli Lehto Töökoht: Genoomika instituut, Tartu Ülikool Töökoha aadress: Riia 23b e-post: [email protected] Uuringu läbi viimise koht: Tartu Ülikooli genoomika instituut , Eesti. Läbivi idava uuringu üldine eesmärk on välja selgitada, kas individuaalsete geneetiliste riskiskooride abil on võimalik eristada vanemaealiste depressiooni ja varajast dementsust juba enne dementsuse diagnoosimist. Selle eesmärgi saavutamiseks on plaanis kasutada geneetilisi andmeid neljast suurest andmekogust (UK Biobank, Eesti geenivaramu, Rootsi kaksikuteregister ja U.S. Health and Retirement Study, summaarne N = 450,000). Eesti bioeetika ja inimuuringute nõukogu on uuringu heaks kiitnud oma 4. aprilli 2020 otsusega nr 1.1-12/ 662 . Uuringu taotluse menetlusest taandas ennast Maarja Kirss, Andmekaitse Inspektsioonist. Valimi moodustab kuni 200 000 geenidoonorit . Andmeandjaks on Eesti Geenivaramu. Uuringu läbi viimise lõpptähtaeg on 31 . märts 20 2 5 . Otsus: anda luba uuringu meeskonna täiendamiseks Otsuse lahutamatu lisad on Tartu Ülikooli Genoomika instituudi jätku taotlus koos lisadega, mis on allkirjastatud vastutava uurija Kelli Lehto poolt 29 . juulil 20 20 . /allkirjastatud digitaalselt/ Liina Vahter Eesti bioeetika ja inimuuringute nõukogu esimees UURIMISTÖÖ AVALDUS KOOSKÕLASTUSE SAAMISEKS EESTI BIOEETIKA JA INIMUURINGUTE NÕUKOGULE 1. UURIMISTÖÖ ANDMED Uurimistöö täielik nimetus: eesti keeles (vajadusel inglise keeles) Individuaalsete geeniandmete rakendamine depressiooni ja dementsuse diagnostikas vanemaealistel Uurimistöö toimumiskoht: Tartu, Eesti 2. UURIMISTÖÖ TEOSTAJAD JA UURINGUKESKUSED 2.1. Vastutav uurija ees- ja perekonnanimi: Kelli Lehto; teaduslik kraad: PhD ; amet: teadur / vanemteadur töökoht: Tervise Arengu Instituut / Genoomika instituut, Tartu Ülikool ; T öökoha aadress: Hiiu 42, Tallinn; telefoninumber: +37253813218 e-post: [email protected] ; allkiri: /allkirjastatud digitaalselt/ 2.2. Kaastöötajad ees- ja perekonnanimi: Reedik Mägi teaduslik kraad: PhD amet: bioinformaatika vanemteadur töökoht: Genoomika instituut, Tartu Ülikool töökoha aadress: Riia 23b/2-517 telefoninumber: 7374045 e-post: reedik.mä[email protected] allkiri: /allkirjastatud digitaalselt/ ees- ja perekonnanimi: Kristi Krebs teaduslik kraad: MSc amet: doktorant töökoht: Genoomika instituut, Tartu Ülikool töökoha aadress: Riia 23b/2-505 telefoninumber: +372 56473303 e-post: [email protected] allkiri: /allkirjastatud digitaalselt/ ees- ja perekonnanimi: Merli Mändul teaduslik kraad: MSc amet: doktorant töökoht: Genoomika instituut, Tartu Ülikool töökoha aadress: Riia 23b-507, Tartu 51010 telefoninumber: +372 737 4042 e-post: [email protected] allkiri: /allkirjastatud digitaalselt/ ees- ja perekonnanimi: Lili Milani teaduslik kraad: PhD amet: farmako - ja epigeneetika juhtivteadur, asedirektor töökoht: Genoomika instituut, Tartu Ülikool töökoha aadress: Riia 23b/2-505 telefoninumber: 53045400 e-post: [email protected] allkiri: /allkirjastatud digitaalselt/ Ees- ja perekonnanimi: Triinu Ojalo Teaduslik kraad: BA psühholoogia Amet: TÜ psühholoogia instituudi magistrant Juhendaja: Kelli Lehto e-post: [email protected] Allkiri: /allkirjastatud digitaalselt/ 2.3.Vastutava uurija asutuse juhataja või tema kohusetäitja on uurimistöö korraldamisega nõus: ees- ja perekonnanimi: Toomas Veidebaum amet: teadusdirektor töökoht: Tervise Arengu Instituut töökoha aadress: Hiiu 42, Tallinn e-post: [email protected] kuupäev: allkiri: /allkirjastatud digitaalselt/ ees- ja perekonnanimi: Mait Metspalu amet: direktor töökoht: Genoomika instituut, Tartu Ülikool töökoha aadress: Riia 23b-303 kuupäev: allkiri: /allkirjastatud digitaalselt/ 3. UURIMISTÖÖ FINANTSEERIMINE Kuna uuringu käigus ei toimu uuritavate värbamist ega proovide võtmist/analüüsi, moodustavad uurimistöö kulu ainult olemasolevaid andmeid analüüsivate teadlaste palgarahad, mis tulevad järgnevatest allikatest: MOBTP142 "Individuaalsete geeniandmete rakendamine depressiooni ja dementsuse diagnostikas vanemaealistel” Uuritavatele kompensatsiooni maksmine: Kuna kasutame uuringu raames vaid eelnevalt kogutud materjali ja andmeid, pole uuritavatele selle projekti raames kompensatsiooni ette nähtud. 4. LÜHIÜLEVAADE SIIANI SAMAL TEEMAL LÄBIVIIDUD UURIMISTÖÖDEST Dementsus, eriti dementsus Alzheimeri tõvest, kujuneb välja pika perioodi vältel ning esimeste sümptomite ilmnemisest diagnoosi saamiseni võib kuluda 10-15 aastat ( prekliiniline periood). Prekliinilisel dementsusel ja vanemaealiste depressioonil on palju kattuvaid sümptomeid, näiteks meeleolu kõikumine, vähenenud sotsiaalsus ning isu-, une- ja mäluhäired. Seetõttu on spetsialistidel raske neid seisundeid omavahel eristada ning määrata igale patsiendile kõige sobivamat ja ohutumat ravi. Aastatepikkune teadustöö on püüdnud välja selgitada, kas depressioonisümptomid on dementsuse riskifaktoriks või hoopis üheks esimeseks sümptomiks. H iljutised suured uuringud on kinnitanud, e t depressioon on dementsuse varajane sümptom, mitte riskitegur ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"a7amdmrq4g","properties":{"formattedCitation":"\\super 1\\nosupersub{}","plainCitation":"1","noteIndex":0},"citationItems":[{"id":1693,"uris":["http://zotero.org/users/2830297/items/K4IPPVIV"],"uri":["http://zotero.org/users/2830297/items/K4IPPVIV"],"itemData":{"id":1693,"type":"article-journal","abstract":"<h3>Importance</h3><p>Neuropsychiatric symptoms, depressive symptoms in particular, are common in patients with dementia but whether depressive symptoms in adulthood increases the risk for dementia remains the subject of debate.</p><h3>Objective</h3><p>To characterize the trajectory of depressive symptoms over 28 years prior to dementia diagnosis to determine whether depressive symptoms carry risk for dementia.</p><h3>Design, Setting, and Participants</h3><p>Up to 10 308 persons, aged 35 to 55 years, were recruited to the Whitehall II cohort study in 1985, with the end of follow-up in 2015. Data analysis for this study in a UK general community was conducted from October to December 2016.</p><h3>Exposures</h3><p>Depressive symptoms assessed on 9 occasions between 1985 and 2012 using the General Health Questionnaire.</p><h3>Main Outcomes and Measures</h3><p>Incidence of dementia (n = 322) between 1985 and 2015.</p><h3>Results</h3><p>Of the 10 189 persons included in the study, 6838 were men (67%) and 3351 were women (33%). Those reporting depressive symptoms in 1985 (mean follow-up, 27 years) did not have significantly increased risk for dementia (hazard ratio [HR], 1.21; 95% CI, 0.95-1.54) in Cox regression adjusted for sociodemographic covariates, health behaviors, and chronic conditions. However, those with depressive symptoms in 2003 (mean follow-up, 11 years) had an increased risk (HR, 1.72; 95% CI, 1.21-2.44). Those with chronic/recurring depressive symptoms (≥2 of 3 occasions) in the early study phase (mean follow-up, 22 years) did not have excess risk (HR, 1.02; 95% CI, 0.72-1.44) but those with chronic/recurring symptoms in the late phase (mean follow-up, 11 years) did have higher risk for dementia (HR, 1.67; 95% CI, 1.11-2.49). Analysis of retrospective depressive trajectories over 28 years, using mixed models and a backward time scale, shows that in those with dementia, differences in depressive symptoms compared with those without dementia became apparent 11 years (difference, 0.61; 95% CI, 0.09-1.13;<i>P</i> = .02) before dementia diagnosis and became more than 9 times larger at the year of diagnosis (difference, 5.81; 95% CI, 4.81-6.81;<i>P</i> < .001).</p><h3>Conclusions and Relevance</h3><p>Depressive symptoms in the early phase of the study corresponding to midlife, even when chronic/recurring, do not increase the risk for dementia. Along with our analysis of depressive trajectories over 28 years, these results suggest that depressive symptoms are a prodromal feature of dementia or that the 2 share common causes. The findings do not support the hypothesis that depressive symptoms increase the risk for dementia.</p>","container-title":"JAMA Psychiatry","DOI":"10.1001/jamapsychiatry.2017.0660","ISSN":"2168-622X","issue":"7","journalAbbreviation":"JAMA Psychiatry","language":"en","page":"712-718","source":"jamanetwork.com","title":"Trajectories of Depressive Symptoms Before Diagnosis of Dementia: A 28-Year Follow-up Study","title-short":"Trajectories of Depressive Symptoms Before Diagnosis of Dementia","volume":"74","author":[{"family":"Singh-Manoux","given":"Archana"},{"family":"Dugravot","given":"Aline"},{"family":"Fournier","given":"Agnes"},{"family":"Abell","given":"Jessica"},{"family":"Ebmeier","given":"Klaus"},{"family":"Kivimäki","given":"Mika"},{"family":"Sabia","given":"Séverine"}],"issued":{"date-parts":[["2017",7,1]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} 1 . Samuti on leitud, et traditsiooniline depressiooni ravi antidepressantidega ei avalda dementsusega patisentidel soovitud mõju ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"8evmZxd8","properties":{"formattedCitation":"\\super 2\\uc0\\u8211{}4\\nosupersub{}","plainCitation":"2–4","noteIndex":0},"citationItems":[{"id":1695,"uris":["http://zotero.org/users/2830297/items/GJGYNRMU"],"uri":["http://zotero.org/users/2830297/items/GJGYNRMU"],"itemData":{"id":1695,"type":"article-journal","abstract":"BACKGROUND: Depression is common in dementia but the evidence base for appropriate drug treatment is sparse and equivocal. We aimed to assess efficacy and safety of two of the most commonly prescribed drugs, sertraline and mirtazapine, compared with placebo.\nMETHODS: We undertook the parallel-group, double-blind, placebo-controlled, Health Technology Assessment Study of the Use of Antidepressants for Depression in Dementia (HTA-SADD) trial in participants from old-age psychiatry services in nine centres in England. Participants were eligible if they had probable or possible Alzheimer's disease, depression (lasting ≥4 weeks), and a Cornell scale for depression in dementia (CSDD) score of 8 or more. Participants were ineligible if they were clinically critical (eg, suicide risk), contraindicated to study drugs, on antidepressants, in another trial, or had no carer. The clinical trials unit at King's College London (UK) randomly allocated participants with a computer-generated block randomisation sequence, stratified by centre, with varying block sizes, in a 1:1:1 ratio to receive sertraline (target dose 150 mg per day), mirtazapine (45 mg), or placebo (control group), all with standard care. The primary outcome was reduction in depression (CSDD score) at 13 weeks (outcomes to 39 weeks were also assessed), assessed with a mixed linear-regression model adjusted for baseline CSDD, time, and treatment centre. This study is registered, number ISRCTN88882979 and EudraCT 2006-000105-38.\nFINDINGS: Decreases in depression scores at 13 weeks did not differ between 111 controls and 107 participants allocated to receive sertraline (mean difference 1·17, 95% CI -0·23 to 2·58; p=0·10) or mirtazapine (0·01, -1·37 to 1·38; p=0·99), or between participants in the mirtazapine and sertraline groups (1·16, -0·25 to 2·57; p=0·11); these findings persisted to 39 weeks. Fewer controls had adverse reactions (29 of 111 [26%]) than did participants in the sertraline group (46 of 107, 43%; p=0·010) or mirtazapine group (44 of 108, 41%; p=0·031), and fewer serious adverse events rated as severe (p=0·003). Five patients in every group died by week 39.\nINTERPRETATION: Because of the absence of benefit compared with placebo and increased risk of adverse events, the present practice of use of these antidepressants, with usual care, for first-line treatment of depression in Alzheimer's disease should be reconsidered.\nFUNDING: UK National Institute of Health Research HTA Programme.","container-title":"Lancet (London, England)","DOI":"10.1016/S0140-6736(11)60830-1","ISSN":"1474-547X","issue":"9789","journalAbbreviation":"Lancet","language":"eng","note":"PMID: 21764118","page":"403-411","source":"PubMed","title":"Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial","title-short":"Sertraline or mirtazapine for depression in dementia (HTA-SADD)","volume":"378","author":[{"family":"Banerjee","given":"Sube"},{"family":"Hellier","given":"Jennifer"},{"family":"Dewey","given":"Michael"},{"family":"Romeo","given":"Renee"},{"family":"Ballard","given":"Clive"},{"family":"Baldwin","given":"Robert"},{"family":"Bentham","given":"Peter"},{"family":"Fox","given":"Chris"},{"family":"Holmes","given":"Clive"},{"family":"Katona","given":"Cornelius"},{"family":"Knapp","given":"Martin"},{"family":"Lawton","given":"Claire"},{"family":"Lindesay","given":"James"},{"family":"Livingston","given":"Gill"},{"family":"McCrae","given":"Niall"},{"family":"Moniz-Cook","given":"Esme"},{"family":"Murray","given":"Joanna"},{"family":"Nurock","given":"Shirley"},{"family":"Orrell","given":"Martin"},{"family":"O'Brien","given":"John"},{"family":"Poppe","given":"Michaela"},{"family":"Thomas","given":"Alan"},{"family":"Walwyn","given":"Rebecca"},{"family":"Wilson","given":"Kenneth"},{"family":"Burns","given":"Alistair"}],"issued":{"date-parts":[["2011",7,30]]}}},{"id":1682,"uris":["http://zotero.org/users/2830297/items/T5D28FN9"],"uri":["http://zotero.org/users/2830297/items/T5D28FN9"],"itemData":{"id":1682,"type":"article-journal","container-title":"Cochrane Database of Systematic Reviews","DOI":"10.1002/14651858.CD003944.pub2","ISSN":"14651858","language":"en","source":"Crossref","title":"Antidepressants for treating depression in dementia","URL":"http://doi.wiley.com.proxy.kib.ki.se/10.1002/14651858.CD003944.pub2","author":[{"family":"Dudas","given":"Robert"},{"family":"Malouf","given":"Reem"},{"family":"McCleery","given":"Jenny"},{"family":"Dening","given":"Tom"}],"editor":[{"literal":"Cochrane Dementia and Cognitive Improvement Group"}],"accessed":{"date-parts":[["2019",1,10]]},"issued":{"date-parts":[["2018",8,31]]}}},{"id":1683,"uris":["http://zotero.org/users/2830297/items/TIM7EAQY"],"uri":["http://zotero.org/users/2830297/items/TIM7EAQY"],"itemData":{"id":1683,"type":"article-journal","abstract":"BACKGROUND: Executive processes consist of at least two sets of functions: one concerned with cognitive control and the other with reward-related decision making. Abnormal performance in both sets occurs in late-life depression. This study tested the hypothesis that only abnormal performance in cognitive control tasks predicts poor outcomes of late-life depression treated with escitalopram.\nMETHOD: We studied older subjects with major depression (N = 53) and non-depressed subjects (N = 30). Executive functions were tested with the Iowa Gambling Test (IGT), Stroop Color-Word Test, Tower of London (ToL), and Dementia Rating Scale - Initiation/Perseveration domain (DRS-IP). After a 2-week placebo washout, depressed subjects received escitalopram (target daily dose: 20 mg) for 12 weeks.\nRESULTS: There were no significant differences between depressed and non-depressed subjects on executive function tests. Hierarchical cluster analysis of depressed subjects identified a Cognitive Control cluster (abnormal Stroop, ToL, DRS-IP), a Reward-Related cluster (IGT), and an Executively Unimpaired cluster. Decline in depression was greater in the Executively Unimpaired (t = -2.09, df = 331, p = 0.0375) and the Reward-Related (t = -2.33, df = 331, p = 0.0202) clusters than the Cognitive Control cluster. The Executively Unimpaired cluster (t = 2.17, df = 331, p = 0.03) and the Reward-Related cluster (t = 2.03, df = 331, p = 0.0433) had a higher probability of remission than the Cognitive Control cluster.\nCONCLUSIONS: Dysfunction of cognitive control functions, but not reward-related decision making, may influence the decline of symptoms and the probability of remission of late-life depression treated with escitalopram. If replicated, simple to administer cognitive control tests may be used to select depressed older patients at risk for poor outcomes to selective serotonin reuptake inhibitors who may require structured psychotherapy.","container-title":"Psychological Medicine","DOI":"10.1017/S0033291715001075","ISSN":"1469-8978","issue":"14","journalAbbreviation":"Psychol Med","language":"eng","note":"PMID: 26169527\nPMCID: PMC4631680","page":"3111-3120","source":"PubMed","title":"Cognitive control, reward-related decision making and outcomes of late-life depression treated with an antidepressant","volume":"45","author":[{"family":"Alexopoulos","given":"G. S."},{"family":"Manning","given":"K."},{"family":"Kanellopoulos","given":"D."},{"family":"McGovern","given":"A."},{"family":"Seirup","given":"J. K."},{"family":"Banerjee","given":"S."},{"family":"Gunning","given":"F."}],"issued":{"date-parts":[["2015",10]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} 2–4 ning teatud antidepressantide tüübid võivad dementsuse puhul lausa olla kahjustava mõjuga ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"yzioSunz","properties":{"formattedCitation":"\\super 5\\uc0\\u8211{}8\\nosupersub{}","plainCitation":"5–8","noteIndex":0},"citationItems":[{"id":1611,"uris":["http://zotero.org/users/2830297/items/PI4KSC9C"],"uri":["http://zotero.org/users/2830297/items/PI4KSC9C"],"itemData":{"id":1611,"type":"article-journal","abstract":"Background\nDepression is associated with cognitive impairment and dementia, but whether treatment for depression with antidepressants reduces the risk for cognitive decline is unclear. We assessed the association between antidepressant use and cognitive decline over 6 years.\nMethods\nParticipants were 3714 adults aged 50 years or more who were enrolled in the nationally representative Health and Retirement Study and had self-reported antidepressant use. Depressive symptoms were assessed using the 8-item Center for Epidemiologic Studies Depression Scale. Cognitive function was assessed at 4 time points (2004, 2006, 2008, 2010) using a validated 27-point scale. Change in cognitive function over the 6-year follow-up period was examined using linear growth models, adjusted for demographics, depressive symptoms, comorbidities, functional limitations, and antidepressant anticholinergic activity load.\nResults\nAt baseline, cognitive function did not differ significantly between the 445 (12.1%) participants taking antidepressants and those not taking antidepressants (mean, 14.9%; 95% confidence interval, 14.3-15.4 vs mean, 15.1%; 95% confidence interval, 14.9-15.3). During the 6-year follow up period, cognition declined in both users and nonusers of antidepressants, ranging from −1.4 change in mean score in those with high depressive symptoms and taking antidepressants to −0.5 change in mean score in those with high depressive symptoms and not taking antidepressants. In adjusted models, cognition declined in people taking antidepressants at the same rate as those not taking antidepressants. Results remained consistent across different levels of baseline cognitive function, age, and duration of antidepressant use (prolonged vs short-term).\nConclusions\nAntidepressant use did not modify the course of 6-year cognitive change in this nationally representative sample.","container-title":"The American Journal of Medicine","DOI":"10.1016/j.amjmed.2015.01.007","ISSN":"0002-9343","issue":"7","journalAbbreviation":"The American Journal of Medicine","page":"739-746","source":"ScienceDirect","title":"Antidepressant Use and Cognitive Decline: The Health and Retirement Study","title-short":"Antidepressant Use and Cognitive Decline","volume":"128","author":[{"family":"Saczynski","given":"Jane S."},{"family":"Rosen","given":"Allison B."},{"family":"McCammon","given":"Ryan J."},{"family":"Zivin","given":"Kara"},{"family":"Andrade","given":"Susan E."},{"family":"Langa","given":"Kenneth M."},{"family":"Vijan","given":"Sandeep"},{"family":"Pirraglia","given":"Paul A."},{"family":"Briesacher","given":"Becky A."}],"issued":{"date-parts":[["2015",7,1]]}}},{"id":1610,"uris":["http://zotero.org/users/2830297/items/6S56CEJ8"],"uri":["http://zotero.org/users/2830297/items/6S56CEJ8"],"itemData":{"id":1610,"type":"article-journal","abstract":"Objectives To estimate the association between the duration and level of exposure to different classes of anticholinergic drugs and subsequent incident dementia.\nDesign Case-control study.\nSetting General practices in the UK contributing to the Clinical Practice Research Datalink.\nParticipants 40 770 patients aged 65-99 with a diagnosis of dementia between April 2006 and July 2015, and 283 933 controls without dementia.\nInterventions Daily defined doses of anticholinergic drugs coded using the Anticholinergic Cognitive Burden (ACB) scale, in total and grouped by subclass, prescribed 4-20 years before a diagnosis of dementia.\nMain outcome measures Odds ratios for incident dementia, adjusted for a range of demographic and health related covariates.\nResults 14 453 (35%) cases and 86 403 (30%) controls were prescribed at least one anticholinergic drug with an ACB score of 3 (definite anticholinergic activity) during the exposure period. The adjusted odds ratio for any anticholinergic drug with an ACB score of 3 was 1.11 (95% confidence interval 1.08 to 1.14). Dementia was associated with an increasing average ACB score. When considered by drug class, gastrointestinal drugs with an ACB score of 3 were not distinctively linked to dementia. The risk of dementia increased with greater exposure for antidepressant, urological, and antiparkinson drugs with an ACB score of 3. This result was also observed for exposure 15-20 years before a diagnosis.\nConclusions A robust association between some classes of anticholinergic drugs and future dementia incidence was observed. This could be caused by a class specific effect, or by drugs being used for very early symptoms of dementia. Future research should examine anticholinergic drug classes as opposed to anticholinergic effects intrinsically or summing scales for anticholinergic exposure.\nTrial registration Registered to the European Union electronic Register of Post-Authorisation Studies EUPAS8705.","container-title":"BMJ","DOI":"10.1136/bmj.k1315","ISSN":"0959-8138, 1756-1833","journalAbbreviation":"BMJ","language":"en","note":"PMID: 29695481","page":"k1315","source":"www.bmj.com","title":"Anticholinergic drugs and risk of dementia: case-control study","title-short":"Anticholinergic drugs and risk of dementia","volume":"361","author":[{"family":"Richardson","given":"Kathryn"},{"family":"Fox","given":"Chris"},{"family":"Maidment","given":"Ian"},{"family":"Steel","given":"Nicholas"},{"family":"Loke","given":"Yoon K."},{"family":"Arthur","given":"Antony"},{"family":"Myint","given":"Phyo K."},{"family":"Grossi","given":"Carlota M."},{"family":"Mattishent","given":"Katharina"},{"family":"Bennett","given":"Kathleen"},{"family":"Campbell","given":"Noll L."},{"family":"Boustani","given":"Malaz"},{"family":"Robinson","given":"Louise"},{"family":"Brayne","given":"Carol"},{"family":"Matthews","given":"Fiona E."},{"family":"Savva","given":"George M."}],"issued":{"date-parts":[["2018",4,25]]}}},{"id":1609,"uris":["http://zotero.org/users/2830297/items/ZGQC6YM2"],"uri":["http://zotero.org/users/2830297/items/ZGQC6YM2"],"itemData":{"id":1609,"type":"article-journal","abstract":"Background\nPotentially inappropriate medication (PIM) is associated with an increased risk for detrimental health outcomes in elderly patients. Some antidepressant drugs are considered as PIM, but previous research on the association between antidepressants and subsequent dementia has been inconclusive. Therefore, we investigated whether the intake of antidepressants, particularly of those considered as PIM according to the Priscus list, would predict incident dementia.\nMethods\nWe used data of a prospective cohort study of non-demented primary care patients (n = 3239, mean age = 79.62) to compute Cox proportional hazards models. The risk for subsequent dementia was estimated over eight follow-ups up to 12 years depending on antidepressant intake and covariates.\nResults\nThe intake of antidepressants was associated with an increased risk for subsequent dementia (HR = 1.53, 95% CI: 1.16–2.02, p = .003; age-, sex-, education-adjusted). PIM antidepressants (HR = 1.49, 95% CI: 1.06–2.10, p = .021), but not other antidepressants (HR = 1.04, 95% CI: 0.66–1.66, p = .863), were associated with an increased risk for subsequent dementia (in age-, sex-, education-, and depressive symptoms adjusted models). Significant associations disappeared after global cognition at baseline was controlled for.\nLimitations\nMethodological limitations such as selection biases and self-reported drug assessments might have influenced the results.\nConclusions\nOnly antidepressants considered as PIM were associated with an increased subsequent dementia risk. Anticholinergic effects might explain this relationship. The association disappeared after the statistical control for global cognition at baseline. Nonetheless, physicians should avoid the prescription of PIM antidepressants in elderly patients whenever possible.","container-title":"Journal of Affective Disorders","DOI":"10.1016/j.jad.2017.09.016","ISSN":"0165-0327","journalAbbreviation":"Journal of Affective Disorders","page":"28-35","source":"ScienceDirect","title":"Potentially inappropriate medication: Association between the use of antidepressant drugs and the subsequent risk for dementia","title-short":"Potentially inappropriate medication","volume":"226","author":[{"family":"Heser","given":"Kathrin"},{"family":"Luck","given":"Tobias"},{"family":"Röhr","given":"Susanne"},{"family":"Wiese","given":"Birgitt"},{"family":"Kaduszkiewicz","given":"Hanna"},{"family":"Oey","given":"Anke"},{"family":"Bickel","given":"Horst"},{"family":"Mösch","given":"Edelgard"},{"family":"Weyerer","given":"Siegfried"},{"family":"Werle","given":"Jochen"},{"family":"Brettschneider","given":"Christian"},{"family":"König","given":"Hans-Helmut"},{"family":"Fuchs","given":"Angela"},{"family":"Pentzek","given":"Michael"},{"family":"Bussche","given":"Hendrik","non-dropping-particle":"van den"},{"family":"Scherer","given":"Martin"},{"family":"Maier","given":"Wolfgang"},{"family":"Riedel-Heller","given":"Steffi G."},{"family":"Wagner","given":"Michael"}],"issued":{"date-parts":[["2018",1,15]]}}},{"id":1608,"uris":["http://zotero.org/users/2830297/items/68L4JLKG"],"uri":["http://zotero.org/users/2830297/items/68L4JLKG"],"itemData":{"id":1608,"type":"article-journal","abstract":"Abstract: We investigated the relationship between antidepressant use and the risk of subsequent dementia development.A population-based retrospective...","container-title":"The Journal of clinical psychiatry","DOI":"10.4088/JCP.14m09580","ISSN":"0160-6689","issue":"1","journalAbbreviation":"J Clin Psychiatry","language":"eng","note":"PMID: 26845268","page":"117-22; quiz 122","source":"europepmc.org","title":"Antidepressant treatment and risk of dementia: a population-based, retrospective case-control study.","title-short":"Antidepressant treatment and risk of dementia","volume":"77","author":[{"family":"Lee","given":"C. W."},{"family":"Lin","given":"C. L."},{"family":"Sung","given":"F. C."},{"family":"Liang","given":"J. A."},{"family":"Kao","given":"C. H."}],"issued":{"date-parts":[["2016",1]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} 5–8 . Seega on spetsialistide jaoks oluline haiguse võimalikult varases faasis kindlaks teha , kas vanemaealisel patsiendil võivad depressioonisümptomid olla seotud hoopis algava dementsusega, et määrata patsiendile õige ravi. Hiljutised arengud geneetilise riskihindamismeetodite arendamisel võimaldavad kasutada geeniandmeid inidividuaalseks haigusriski hindamiseks , seejuures ka parandades diagnostiliste- ja raviotsuste täpsust ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"ogHEjShd","properties":{"formattedCitation":"\\super 9\\uc0\\u8211{}12\\nosupersub{}","plainCitation":"9–12","noteIndex":0},"citationItems":[{"id":1651,"uris":["http://zotero.org/users/2830297/items/PJZY6HYZ"],"uri":["http://zotero.org/users/2830297/items/PJZY6HYZ"],"itemData":{"id":1651,"type":"article-journal","abstract":"Polygenic risk profiling can lead to actionable outcomes for individuals at high risk of developing a subset of common adult-onset polygenic diseases. The authors review recent studies that have demonstrated the utility of polygenic risk scores for disease risk stratification and their potential impact on early disease detection, prevention, therapeutic intervention and life planning.","container-title":"Nature Reviews Genetics","DOI":"10.1038/s41576-018-0018-x","ISSN":"1471-0064","issue":"9","language":"En","page":"581","source":"www-nature-com.proxy.kib.ki.se","title":"The personal and clinical utility of polygenic risk scores","volume":"19","author":[{"family":"Torkamani","given":"Ali"},{"family":"Wineinger","given":"Nathan E."},{"family":"Topol","given":"Eric J."}],"issued":{"date-parts":[["2018",9]]}}},{"id":1689,"uris":["http://zotero.org/users/2830297/items/BUIJB774"],"uri":["http://zotero.org/users/2830297/items/BUIJB774"],"itemData":{"id":1689,"type":"article-journal","abstract":"Genome-wide polygenic risk scores derived from GWAS data for five common diseases can identify subgroups of the population with risk approaching or exceeding that of a monogenic mutation.","container-title":"Nature Genetics","DOI":"10.1038/s41588-018-0183-z","ISSN":"1546-1718","issue":"9","language":"En","page":"1219","source":"www.nature.com","title":"Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations","volume":"50","author":[{"family":"Khera","given":"Amit V."},{"family":"Chaffin","given":"Mark"},{"family":"Aragam","given":"Krishna G."},{"family":"Haas","given":"Mary E."},{"family":"Roselli","given":"Carolina"},{"family":"Choi","given":"Seung Hoan"},{"family":"Natarajan","given":"Pradeep"},{"family":"Lander","given":"Eric S."},{"family":"Lubitz","given":"Steven A."},{"family":"Ellinor","given":"Patrick T."},{"family":"Kathiresan","given":"Sekar"}],"issued":{"date-parts":[["2018",9]]}}},{"id":1616,"uris":["http://zotero.org/users/2830297/items/F242NIQT"],"uri":["http://zotero.org/users/2830297/items/F242NIQT"],"itemData":{"id":1616,"type":"article-journal","abstract":"Depression was a late arrival at the genome-wide association study discovery party, with early meta-analyses showing no evidence for genetic variants associated","container-title":"JAMA Psychiatry","DOI":"10.1001/jamapsychiatry.2018.3975","journalAbbreviation":"JAMA Psychiatry","language":"en","source":"jamanetwork-com.proxy.kib.ki.se","title":"Progressing Polygenic Medicine in Psychiatry Through Electronic Health Records","URL":"https://jamanetwork-com.proxy.kib.ki.se/journals/jamapsychiatry/fullarticle/2722561","author":[{"family":"Lewis","given":"Cathryn M."},{"family":"Hagenaars","given":"Saskia P."}],"accessed":{"date-parts":[["2019",1,31]]},"issued":{"date-parts":[["2019",1,30]]}}},{"id":1679,"uris":["http://zotero.org/users/2830297/items/2RKFPUMY"],"uri":["http://zotero.org/users/2830297/items/2RKFPUMY"],"itemData":{"id":1679,"type":"article-journal","abstract":"BackgroundFamily history is a long-standing and readily obtainable risk factor for schizophrenia (SCZ). Low-cost genotyping technologies have enabled large genetic studies of SCZ, and the results suggest the utility of genetic risk scores (GRS, direct assessments of inherited common variant risk). Few studies have evaluated family history and GRS simultaneously to ask whether one can explain away the other.MethodsWe studied 5959 SCZ cases and 8717 controls from four Nordic countries. All subjects had family history data from national registers and genome-wide genotypes that were processed through the quality control procedures used by the Psychiatric Genomics Consortium. Using external training data, GRS were estimated for SCZ, bipolar disorder (BIP), major depression, autism, educational attainment, and body mass index. Multivariable modeling was used to estimate effect sizes.ResultsUsing harmonized genomic and national register data from Denmark, Estonia, Norway, and Sweden, we confirmed that family history of SCZ and GRS for SCZ and BIP were risk factors for SCZ. In a joint model, the effects of GRS for SCZ and BIP were essentially unchanged, and the effect of family history was attenuated but remained significant. The predictive capacity of a model including GRS and family history neared the minimum for clinical utility.ConclusionsCombining national register data with measured genetic risk factors represents an important investigative approach for psychotic disorders. Our findings suggest the potential clinical utility of combining GRS and family history for early prediction and diagnostic improvements.","container-title":"Psychological Medicine","DOI":"10.1017/S0033291717002665","ISSN":"0033-2917, 1469-8978","issue":"7","language":"en","page":"1201-1208","source":"Cambridge Core","title":"Genetic risk scores and family history as predictors of schizophrenia in Nordic registers","volume":"48","author":[{"family":"Lu","given":"Y."},{"family":"Pouget","given":"J. G."},{"family":"Andreassen","given":"O. A."},{"family":"Djurovic","given":"S."},{"family":"Esko","given":"T."},{"family":"Hultman","given":"C. M."},{"family":"Metspalu","given":"A."},{"family":"Milani","given":"L."},{"family":"Werge","given":"T."},{"family":"Sullivan","given":"P. F."}],"issued":{"date-parts":[["2018",5]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} 9–12 . Üheks keskseks meetodiks, mis sellist riskihindamist võimaldab, on geneetiliste riskiskooride (GRS) kasutamine. GRSi arvutamiseks kasutatakse suurte ülegenoomsete assotsiatsiooniuuringute ( genoome- wide association study ; GWAS) tulemusi haigusega seotud ühenukleotiidiliste polümorfismide ( single nucleotide polymorphism ; SNPide ) riskialleelide ja efekti suuruste kohta, et arvutada individuaalne geneetiline risk teisel populatsioonil (mis ei olnud kaasatud algsesse ülegenoomsesse assotsiatsiooniuuringusse). GRSide võimekus haigusriskide hindamisel sõltub nii konkreetse haiguse geneetilisest ülesehitusest kui ka GWASi võimsusest. Kõige hiljutisemate d epressiooni ja Alzheimeri GWASide põhjal loodud GRS-id juba võimaldavad identifitseerida kõrge haigusriskiga indiviide ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"ILCYfeuk","properties":{"formattedCitation":"\\super 13,14\\nosupersub{}","plainCitation":"13,14","noteIndex":0},"citationItems":[{"id":1688,"uris":["http://zotero.org/users/2830297/items/PPB5PPEI"],"uri":["http://zotero.org/users/2830297/items/PPB5PPEI"],"itemData":{"id":1688,"type":"article-journal","abstract":"A genome-wide association meta-analysis of individuals with clinically assessed or self-reported depression identifies 44 independent risk loci. Comparisons with other psychiatric disorders and candidate gene analyses provide new insights into major depressive disorder.","container-title":"Nature Genetics","DOI":"10.1038/s41588-018-0090-3","ISSN":"1546-1718","issue":"5","language":"En","page":"668","source":"www.nature.com","title":"Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression","volume":"50","author":[{"family":"Wray","given":"Naomi R."},{"family":"Ripke","given":"Stephan"},{"family":"Mattheisen","given":"Manuel"},{"family":"Trzaskowski","given":"Maciej"},{"family":"Byrne","given":"Enda M."},{"family":"Abdellaoui","given":"Abdel"},{"family":"Adams","given":"Mark J."},{"family":"Agerbo","given":"Esben"},{"family":"Air","given":"Tracy M."},{"family":"Andlauer","given":"Till M. F."},{"family":"Bacanu","given":"Silviu-Alin"},{"family":"Bækvad-Hansen","given":"Marie"},{"family":"Beekman","given":"Aartjan F. T."},{"family":"Bigdeli","given":"Tim B."},{"family":"Binder","given":"Elisabeth B."},{"family":"Blackwood","given":"Douglas R. H."},{"family":"Bryois","given":"Julien"},{"family":"Buttenschøn","given":"Henriette N."},{"family":"Bybjerg-Grauholm","given":"Jonas"},{"family":"Cai","given":"Na"},{"family":"Castelao","given":"Enrique"},{"family":"Christensen","given":"Jane Hvarregaard"},{"family":"Clarke","given":"Toni-Kim"},{"family":"Coleman","given":"Jonathan I. R."},{"family":"Colodro-Conde","given":"Lucía"},{"family":"Couvy-Duchesne","given":"Baptiste"},{"family":"Craddock","given":"Nick"},{"family":"Crawford","given":"Gregory E."},{"family":"Crowley","given":"Cheynna A."},{"family":"Dashti","given":"Hassan S."},{"family":"Davies","given":"Gail"},{"family":"Deary","given":"Ian J."},{"family":"Degenhardt","given":"Franziska"},{"family":"Derks","given":"Eske M."},{"family":"Direk","given":"Nese"},{"family":"Dolan","given":"Conor V."},{"family":"Dunn","given":"Erin C."},{"family":"Eley","given":"Thalia C."},{"family":"Eriksson","given":"Nicholas"},{"family":"Escott-Price","given":"Valentina"},{"family":"Kiadeh","given":"Farnush Hassan Farhadi"},{"family":"Finucane","given":"Hilary K."},{"family":"Forstner","given":"Andreas J."},{"family":"Frank","given":"Josef"},{"family":"Gaspar","given":"Héléna A."},{"family":"Gill","given":"Michael"},{"family":"Giusti-Rodríguez","given":"Paola"},{"family":"Goes","given":"Fernando S."},{"family":"Gordon","given":"Scott D."},{"family":"Grove","given":"Jakob"},{"family":"Hall","given":"Lynsey S."},{"family":"Hannon","given":"Eilis"},{"family":"Hansen","given":"Christine Søholm"},{"family":"Hansen","given":"Thomas F."},{"family":"Herms","given":"Stefan"},{"family":"Hickie","given":"Ian B."},{"family":"Hoffmann","given":"Per"},{"family":"Homuth","given":"Georg"},{"family":"Horn","given":"Carsten"},{"family":"Hottenga","given":"Jouke-Jan"},{"family":"Hougaard","given":"David M."},{"family":"Hu","given":"Ming"},{"family":"Hyde","given":"Craig L."},{"family":"Ising","given":"Marcus"},{"family":"Jansen","given":"Rick"},{"family":"Jin","given":"Fulai"},{"family":"Jorgenson","given":"Eric"},{"family":"Knowles","given":"James A."},{"family":"Kohane","given":"Isaac S."},{"family":"Kraft","given":"Julia"},{"family":"Kretzschmar","given":"Warren W."},{"family":"Krogh","given":"Jesper"},{"family":"Kutalik","given":"Zoltán"},{"family":"Lane","given":"Jacqueline M."},{"family":"Li","given":"Yihan"},{"family":"Li","given":"Yun"},{"family":"Lind","given":"Penelope A."},{"family":"Liu","given":"Xiaoxiao"},{"family":"Lu","given":"Leina"},{"family":"MacIntyre","given":"Donald J."},{"family":"MacKinnon","given":"Dean F."},{"family":"Maier","given":"Robert M."},{"family":"Maier","given":"Wolfgang"},{"family":"Marchini","given":"Jonathan"},{"family":"Mbarek","given":"Hamdi"},{"family":"McGrath","given":"Patrick"},{"family":"McGuffin","given":"Peter"},{"family":"Medland","given":"Sarah E."},{"family":"Mehta","given":"Divya"},{"family":"Middeldorp","given":"Christel M."},{"family":"Mihailov","given":"Evelin"},{"family":"Milaneschi","given":"Yuri"},{"family":"Milani","given":"Lili"},{"family":"Mill","given":"Jonathan"},{"family":"Mondimore","given":"Francis M."},{"family":"Montgomery","given":"Grant W."},{"family":"Mostafavi","given":"Sara"},{"family":"Mullins","given":"Niamh"},{"family":"Nauck","given":"Matthias"},{"family":"Ng","given":"Bernard"},{"family":"Nivard","given":"Michel G."},{"family":"Nyholt","given":"Dale R."},{"family":"O’Reilly","given":"Paul F."},{"family":"Oskarsson","given":"Hogni"},{"family":"Owen","given":"Michael J."},{"family":"Painter","given":"Jodie N."},{"family":"Pedersen","given":"Carsten Bøcker"},{"family":"Pedersen","given":"Marianne Giørtz"},{"family":"Peterson","given":"Roseann E."},{"family":"Pettersson","given":"Erik"},{"family":"Peyrot","given":"Wouter J."},{"family":"Pistis","given":"Giorgio"},{"family":"Posthuma","given":"Danielle"},{"family":"Purcell","given":"Shaun M."},{"family":"Quiroz","given":"Jorge A."},{"family":"Qvist","given":"Per"},{"family":"Rice","given":"John P."},{"family":"Riley","given":"Brien P."},{"family":"Rivera","given":"Margarita"},{"family":"Mirza","given":"Saira Saeed"},{"family":"Saxena","given":"Richa"},{"family":"Schoevers","given":"Robert"},{"family":"Schulte","given":"Eva C."},{"family":"Shen","given":"Ling"},{"family":"Shi","given":"Jianxin"},{"family":"Shyn","given":"Stanley I."},{"family":"Sigurdsson","given":"Engilbert"},{"family":"Sinnamon","given":"Grant B. C."},{"family":"Smit","given":"Johannes H."},{"family":"Smith","given":"Daniel J."},{"family":"Stefansson","given":"Hreinn"},{"family":"Steinberg","given":"Stacy"},{"family":"Stockmeier","given":"Craig A."},{"family":"Streit","given":"Fabian"},{"family":"Strohmaier","given":"Jana"},{"family":"Tansey","given":"Katherine E."},{"family":"Teismann","given":"Henning"},{"family":"Teumer","given":"Alexander"},{"family":"Thompson","given":"Wesley"},{"family":"Thomson","given":"Pippa A."},{"family":"Thorgeirsson","given":"Thorgeir E."},{"family":"Tian","given":"Chao"},{"family":"Traylor","given":"Matthew"},{"family":"Treutlein","given":"Jens"},{"family":"Trubetskoy","given":"Vassily"},{"family":"Uitterlinden","given":"André G."},{"family":"Umbricht","given":"Daniel"},{"family":"Auwera","given":"Sandra Van","dropping-particle":"der"},{"family":"Hemert","given":"Albert M.","dropping-particle":"van"},{"family":"Viktorin","given":"Alexander"},{"family":"Visscher","given":"Peter M."},{"family":"Wang","given":"Yunpeng"},{"family":"Webb","given":"Bradley T."},{"family":"Weinsheimer","given":"Shantel Marie"},{"family":"Wellmann","given":"Jürgen"},{"family":"Willemsen","given":"Gonneke"},{"family":"Witt","given":"Stephanie H."},{"family":"Wu","given":"Yang"},{"family":"Xi","given":"Hualin S."},{"family":"Yang","given":"Jian"},{"family":"Zhang","given":"Futao"},{"family":"Arolt","given":"Volker"},{"family":"Baune","given":"Bernhard T."},{"family":"Berger","given":"Klaus"},{"family":"Boomsma","given":"Dorret I."},{"family":"Cichon","given":"Sven"},{"family":"Dannlowski","given":"Udo"},{"family":"Geus","given":"E. C. J.","dropping-particle":"de"},{"family":"DePaulo","given":"J. Raymond"},{"family":"Domenici","given":"Enrico"},{"family":"Domschke","given":"Katharina"},{"family":"Esko","given":"Tõnu"},{"family":"Grabe","given":"Hans J."},{"family":"Hamilton","given":"Steven P."},{"family":"Hayward","given":"Caroline"},{"family":"Heath","given":"Andrew C."},{"family":"Hinds","given":"David A."},{"family":"Kendler","given":"Kenneth S."},{"family":"Kloiber","given":"Stefan"},{"family":"Lewis","given":"Glyn"},{"family":"Li","given":"Qingqin S."},{"family":"Lucae","given":"Susanne"},{"family":"Madden","given":"Pamela F. A."},{"family":"Magnusson","given":"Patrik K."},{"family":"Martin","given":"Nicholas G."},{"family":"McIntosh","given":"Andrew M."},{"family":"Metspalu","given":"Andres"},{"family":"Mors","given":"Ole"},{"family":"Mortensen","given":"Preben Bo"},{"family":"Müller-Myhsok","given":"Bertram"},{"family":"Nordentoft","given":"Merete"},{"family":"Nöthen","given":"Markus M."},{"family":"O’Donovan","given":"Michael C."},{"family":"Paciga","given":"Sara A."},{"family":"Pedersen","given":"Nancy L."},{"family":"Penninx","given":"Brenda W. J. H."},{"family":"Perlis","given":"Roy H."},{"family":"Porteous","given":"David J."},{"family":"Potash","given":"James B."},{"family":"Preisig","given":"Martin"},{"family":"Rietschel","given":"Marcella"},{"family":"Schaefer","given":"Catherine"},{"family":"Schulze","given":"Thomas G."},{"family":"Smoller","given":"Jordan W."},{"family":"Stefansson","given":"Kari"},{"family":"Tiemeier","given":"Henning"},{"family":"Uher","given":"Rudolf"},{"family":"Völzke","given":"Henry"},{"family":"Weissman","given":"Myrna M."},{"family":"Werge","given":"Thomas"},{"family":"Winslow","given":"Ashley R."},{"family":"Lewis","given":"Cathryn M."},{"family":"Levinson","given":"Douglas F."},{"family":"Breen","given":"Gerome"},{"family":"Børglum","given":"Anders D."},{"family":"Sullivan","given":"Patrick F."}],"issued":{"date-parts":[["2018",5]]}}},{"id":1650,"uris":["http://zotero.org/users/2830297/items/KGMBBHZ3"],"uri":["http://zotero.org/users/2830297/items/KGMBBHZ3"],"itemData":{"id":1650,"type":"article-journal","abstract":"BACKGROUND: Identifying individuals at risk for developing Alzheimer disease (AD) is of utmost importance. Although genetic studies have identified AD-associated SNPs in APOE and other genes, genetic information has not been integrated into an epidemiological framework for risk prediction.\nMETHODS AND FINDINGS: Using genotype data from 17,008 AD cases and 37,154 controls from the International Genomics of Alzheimer's Project (IGAP Stage 1), we identified AD-associated SNPs (at p < 10-5). We then integrated these AD-associated SNPs into a Cox proportional hazard model using genotype data from a subset of 6,409 AD patients and 9,386 older controls from Phase 1 of the Alzheimer's Disease Genetics Consortium (ADGC), providing a polygenic hazard score (PHS) for each participant. By combining population-based incidence rates and the genotype-derived PHS for each individual, we derived estimates of instantaneous risk for developing AD, based on genotype and age, and tested replication in multiple independent cohorts (ADGC Phase 2, National Institute on Aging Alzheimer's Disease Center [NIA ADC], and Alzheimer's Disease Neuroimaging Initiative [ADNI], total n = 20,680). Within the ADGC Phase 1 cohort, individuals in the highest PHS quartile developed AD at a considerably lower age and had the highest yearly AD incidence rate. Among APOE ε3/3 individuals, the PHS modified expected age of AD onset by more than 10 y between the lowest and highest deciles (hazard ratio 3.34, 95% CI 2.62-4.24, p = 1.0 × 10-22). In independent cohorts, the PHS strongly predicted empirical age of AD onset (ADGC Phase 2, r = 0.90, p = 1.1 × 10-26) and longitudinal progression from normal aging to AD (NIA ADC, Cochran-Armitage trend test, p = 1.5 × 10-10), and was associated with neuropathology (NIA ADC, Braak stage of neurofibrillary tangles, p = 3.9 × 10-6, and Consortium to Establish a Registry for Alzheimer's Disease score for neuritic plaques, p = 6.8 × 10-6) and in vivo markers of AD neurodegeneration (ADNI, volume loss within the entorhinal cortex, p = 6.3 × 10-6, and hippocampus, p = 7.9 × 10-5). Additional prospective validation of these results in non-US, non-white, and prospective community-based cohorts is necessary before clinical use.\nCONCLUSIONS: We have developed a PHS for quantifying individual differences in age-specific genetic risk for AD. Within the cohorts studied here, polygenic architecture plays an important role in modifying AD risk beyond APOE. With thorough validation, quantification of inherited genetic variation may prove useful for stratifying AD risk and as an enrichment strategy in therapeutic trials.","container-title":"PLoS medicine","DOI":"10.1371/journal.pmed.1002258","ISSN":"1549-1676","issue":"3","journalAbbreviation":"PLoS Med.","language":"eng","note":"PMID: 28323831\nPMCID: PMC5360219","page":"e1002258","source":"PubMed","title":"Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score","title-short":"Genetic assessment of age-associated Alzheimer disease risk","volume":"14","author":[{"family":"Desikan","given":"Rahul S."},{"family":"Fan","given":"Chun Chieh"},{"family":"Wang","given":"Yunpeng"},{"family":"Schork","given":"Andrew J."},{"family":"Cabral","given":"Howard J."},{"family":"Cupples","given":"L. Adrienne"},{"family":"Thompson","given":"Wesley K."},{"family":"Besser","given":"Lilah"},{"family":"Kukull","given":"Walter A."},{"family":"Holland","given":"Dominic"},{"family":"Chen","given":"Chi-Hua"},{"family":"Brewer","given":"James B."},{"family":"Karow","given":"David S."},{"family":"Kauppi","given":"Karolina"},{"family":"Witoelar","given":"Aree"},{"family":"Karch","given":"Celeste M."},{"family":"Bonham","given":"Luke W."},{"family":"Yokoyama","given":"Jennifer S."},{"family":"Rosen","given":"Howard J."},{"family":"Miller","given":"Bruce L."},{"family":"Dillon","given":"William P."},{"family":"Wilson","given":"David M."},{"family":"Hess","given":"Christopher P."},{"family":"Pericak-Vance","given":"Margaret"},{"family":"Haines","given":"Jonathan L."},{"family":"Farrer","given":"Lindsay A."},{"family":"Mayeux","given":"Richard"},{"family":"Hardy","given":"John"},{"family":"Goate","given":"Alison M."},{"family":"Hyman","given":"Bradley T."},{"family":"Schellenberg","given":"Gerard D."},{"family":"McEvoy","given":"Linda K."},{"family":"Andreassen","given":"Ole A."},{"family":"Dale","given":"Anders M."}],"issued":{"date-parts":[["2017"]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} 13,14 . Seega võib GRSidel olla suur potentsiaal algava dementsuse ja vanemaealiste depressiooni varajaseks eristamiseks . 5. KAVANDATAVA UURIMISTÖÖ EESMÄRK, KOKKUVÕTE JA PÕHJENDUS Käesoleva projekti eesmärgiks on välja selgitada, kas individuaalsete geneetiliste riskiskooride abil on võimalik eristada vanemaealiste depressiooni ja varajast dementsust juba enne dementsuse diagnoosimist. Selle eesmärgi saavutamiseks on plaanis kasutada geneetilisi andmeid neljast suurest andmekogust (UK Biobank , Eesti g eenivaramu, Rootsi kaksikuteregister ja U.S. Health and Retirement Study , summaarne N = 450,000). Käesolev taotlus on suunatud Eesti g eenivaramu (EGV) andmestiku kasutamiseks. Teiste andmestike kasutamiseks on juba olemas kehtivad eetikakomiteede nõusolekud (vt. punkt 1 1 ). Projekti käigus uuritakse hüpoteesi , et dementsusele eelnevad depressiooni sümptomid on geneetiliselt rohkem seotud dementsuse kui depressiooni ga. Lisaks testitakse, millises vanuses on sellisel viisil dementsuse geneetiline riskihindamine optimaalseim . Projekti käigus käsitletakse erinevaid dementsuse vorme nii eraldiseisvatena ( Alzheimeri tõbi, vaskulaarne dementsus) kui ka dementsuse erinevaid vorme eristamata (all- cause dementia ). Projekti tulemustel on suur potentsiaal avada uusi võimalusi kasutamaks individuaalseid geneetilisi riskiskoore personaalmeditsiinile orienteeritud tervishoiusüsteemides. 6. UURIMISTÖÖ TEOSTAMISE AEG 0 4 /2020 - 0 3 /202 5 7. UURITAVATE JA NENDE VÄRBAMISVIISI TÄPNE KIRJELDUS Uuringus kasutatakse ainult juba kogutud pseudonüümitud andmeid Eesti g eenivaramust kõikide indiviidide kohta, k elle kohta on olemas nii genotüübiandmed kui ka punktis 8 toodud fenotüübiandmed (Eesti Haigekassa (EHK) andmebaasist , surmapõhjuste registrist ja EGV geenidoonorite standard küsimustikest). EGV linkimine EHK ja surmapõhjuste registriga toimub regulaarselt umbes üks kord aastas ning eraldi linkimist selle projekti elluviimiseks ei tehta. Hetkel on EHK and surmapõhjuste registrist pärinevad andmed vastavalt 31.12.2018 ja 14.06.2019 seisuga. EGV geenidoonorite terviseandmete standardküsimustiku on geenidoonorid täitnud geeivaramuga liitumisel. Kõikidele geenidoonoritele, kellel on allkirjastatud nõusoleku vorm ja kelle vereproov on jõudnud geenivaramusse on saadetud e-mail küsimustiku lingiga. Käesoleva projekti v alimi aluseks on kõik Eesti geenivaramu geenidoonorid ( ligi kaudu 200 000 indiviidi ) , kellest hinnanguliselt 27% on depressioonidiagnoosiga ning 1% dementsuse diagnoosiga. Kuna linkimine Eesti Haigekassa andmebaasiga ei ole veel hiljuti juurde lisandunud geenidoonorite puhul lõpule viidud, ei saa ka hetkel öelda täpseid diagnoosiga patsientide arvu EGV-s. Tuginedes vaid hetkel olemasolevatele andmetele (umbkaudu 139 000 indiviidi kohta) on EGV-s 1476 dementsuse diagnoosiga patsienti, kellest 313 on Alzheimeri tõve diagoosiga . Depressiooni diagnoosiga patsiente on EGV-s hetkeseisuga 35162. 8. UURIMISMETOODIKA TÄPNE KIRJELDUS Uuringus kasutatakse eelnevalt kogutud andmeid (Eesti g eenivaramu), sealhulgas geneetilisi andmeid ning depressiooni ja dementsus sündroomide ( Alzheimer’i tõbi, vaskulaarne dementsus, frontitemporaalne dementsus, Lewy kehakeste dementsus , täpsustamata dementsus ) ning nende haiguste ravimi te kasutamise kohta käivaid isikustamata fenotüübiandmeid. Kuna teatud dementsuse vormid on tugevalt seotud kardiovaskulaarsüsteemi häiretega ( vaskulaarne dementsus), siis kaasatakse uuringusse ka kardiovaskulaarhaiguste geneetilised riskifaktorid ja fenotüübid. Andmed diagnooside ja ravimikasutuse kohta tulevad Eesti Haigekass a andmebaasist (raviarvetelt pärinevad andmed) , millega EGV andmestikku regulaarselt lingitakse. Seega selle projekti raames kasutatakse juba lingitud andmeid ning lähiaasta jooksul saabuvaid lingit ud andmeid uute (2019a liitunud ) geenidoonorite kohta , kes on lubanud oma andmete täiendamise linkimise teel . EGV linkimine EHK andmebaasiga toimub regulaarselt umbes üks kord aastas ning eraldi linkimist selle projekti elluviimiseks ei tehta. Dementsuse erinevate vormide defineerimine toimub varem kirjeldatud meetodil, tagamaks tulemuste võrreldavus teise suure kohortuuringuga Inglismaal (UK Biobank ; meetodi detailne kirjeldus: http://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/alg_outcome_dementia.pdf ). Dementsuse erinevate vormide täpsed definitsioonid on leitavad Tabelist 1. Hüpoteeside testimiseks kasutatakse peamiselt erinevaid regressioonanalüüsi meetodeid (lineaarne ja logistiline regressioon). Analüüsides võetakse arvesse geenidoonorite vanust ning teisi analüüsi-spetsiifilisi kovariaate . Andmeanalüüsi läbiviimisel kasutatakse vastava valdkonna standardtarkvara, mis võimaldab analüüsida tunnuste omavahelisi seoseid ning läbi viia meta -analüüse (STATA, R) . Geneetilised riskiskoorid depressiooni/depressiooni sümptomite, Alzheimer’i tõve ja kardiovaskulaarsete haiguste kohta koostatakse Eesti geenivaramu andmestikul kasutades standardtarkvara LDpred . EGV andmetel läbiviidav andmeanalüüs viiakse läbi Eestis ning samuti toimub Eestis igal andmestikul läbiviidud analüüsitulemuste metaanalüüs . Kõikide andmete ettevalmistuse ning andmeanalüüside skriptid salvestatakse juhuks kui tulevikus ilmeb vajadus tulemusi reprodutseerida. Tunnuste loetelu: Ülegenoomsed genotüübiandmed ja nende põhjal arvutatud geneetilised riskiskoorid depressiooni/depressiooni sümptomite, Alzheimer’i tõve ja k ardiovaskulaarsete haiguste (südame isheemiatõbi, insult) kohta. Depressiooni ja dementsuse ning nendega seotud fenotüübiandmed Diagnoosid ja tervishoiuteenused alates aastast 2004 kuni viimase linkimiseni : Eesti Haigekassa tervishoiuteenuste andmebaasist esmased raviarved (varasemalt juba lingitud EGV- ga ) , millel esinevad RHK-10 alusel diagnoosikoodid F00-F99, G00-G99, I00-I99 ning tervishoiuteenus 7609 Ravimikasutus alates aastast 2004 kuni viimase linkimiseni : Eesti Haigekassa tervishoiuteenuste andmebaasist digiretsepti andmed (ATC rühmad: C1-C10; N1-N07), retseptide väljakirjutamise kuupäev, väljaostmiskuupäev, ostetud ravimipakendi kood ning ostetud pakendite arv Surmapõhjused s urmapõhjuste registrist Nimetatud haigusgruppidega seonduvad andmed EGV geenidoonorite terviseandmete küsimustik u st vastamise hetkel ( pikkus, kaal, suitsetamine, füüsiline aktiivsus, toitumine) Demograafilised tunnused EGV geenidoonorite terviseandmete küsimustik u st vastamise hetkel ( sünniaasta , sugu, haridustase, perekonnaseis) Tabel 1. Alzheimeri tõve, vaskulaarse dementsuse ja üldise dementsuse (kõik dementsust hõlmavad diagnoosid) definitsioonid RHK 10 diagnoosid Alzheimeri tõbi Vaskulaarne dementsus Üldine dementsus A81.0 x F00 x x F00.0 x x F00.1 x x F00.2 x x F00.9 x x F01 x x F01.0 x x F01.1 x x F01.2 x x F01.3 x x F01.8 x x F01.9 x x F02 x F02.0 x F02.1 x F02.2 x F02.3 x F02.4 x F02.8 x F03 x F05.1 x F10.6 x F10.73 x G30 x x G30.0 x x G30.1 x x G30.8 x x G30.9 x x G31.0 x G31.1 x G31.8 x I67.3 x x 9. UURIMISTÖÖ EETILISTE ASPEKTIDE KIRJELDUS 1) Isiku autonoomia respekteerimise printsiip: Uuringu läbiviimisel lähtutakse Inimgeeniuuringute seadusest (IGUS). Geenidoonorid on liitunud EGVga vabatahtlikkuse alusel (IGUS §9) ning allkirjastanud geenidoonoriks saamise nõusoleku vormi peale infolehega tutvumist (vt. Nõusoleku vormi määrus: https://www.riigiteataja.ee/akt/117042019016 ning infoleht: https://geenidoonor.ee/infoleht ) . Geenidoonoritel on õigus enda nõusolek igal ajal tagasi võtta (IGUS § 12) , aga ka taotleda depseudonümiseeritud andmete hävitamist . Lisaks on geenidoonoritel õigus keelata oma andmete täiendamise teistest andmekogudest (IGUS §11) ning sellisel juhul teiste andmekogudega (nt. Eesti Haigekassa andmebaas) linkimist nende geenidoonorite andmetega ei toimu. 2) Mittekahjustamise printsiip: Uuringus kasutatakse ainult geenivaramu andmebaasis olemasolevaid geenidoonorite andmeid isikustamata ( pseudonümiseeritud ) kujul. Vastutava uurija hinnangul ei ole EGVst päritavate tunnuste alusel uuritavad kaudselt tuvastatavad. Uuringu käigus ei võeta geenidoonoritega uuesti ühendust ning ei võeta lisaproove ega teostata lisamõõtmisi. Seega ei põhjustata uuritavatele terviseriske ega lisakoormust. Avaldatakse ainult analüüside koondstatistikuid, mis ei võimalda uuringus osalejate re -identifitseerimist. Uuringu tulemused ei kahjusta geenidoonoreid mitte mingil moel. Pigem saab uuringust tulevikus kasu kogu Eesti rahvastik, kuna rahvastik vananeb ning vananemisega seotud haigused põhjustavad järjest suuremat koormust nii ühiskonnale kui ka patsientidele ja nende perekondadele. 3) Heategemise ja õigluse printsiip: Uurimistöö tulemused on vajalikud arendamaks ja rakendamaks personaalmeditsiini Eestis. Uurimistööst saadavad tulemused toovad kasu võrdselt kõikidele geenidoonoritele, aga ka teistele Eesti elanikele. Töö üldistatud tulemusi jagatakse laiema avalikkusega ning publitseeritakse rahvusvahelistes eelretsenseeritud ajakirjades, et edendada valdkonna teadmisi. 10. UURIMISTÖÖ ANDMEKAITSELISTE ASPEKTIDE KIRJELDUS Seaduslik alus geenivaramust andmete väljastamiseks Geenivaramust väljastatakse uurimistööks koeproove, DNA kirjeldusi või terviseseisundi kirjeldusi ainult pseudonüümituna, hulgana ja tingimusel, et väljastatavaid proove või andmeid on üheaegselt vähemalt viie geenidoonori kohta ( IGUS § 22, lg (4 )). Andmete geenivaramust väljastamise protseduur Andmete väljastamisel järgib geenivaramu kõiki IGUSest tulenevaid nõudeid. Väljastuse eelduseks on Eesti bioeetika ja inimuuringute nõukogu hinnang. TÜ Genoomika instituudi direktori korraldusega määratakse nimeliselt väljastustoimingute teostamise eest vastutavad isikud. TÜ Genoomika instituudi direktor annab korralduse andmete väljastamiseks. Koostatakse väljastamisprotokoll, kuhu märgitakse väljastatud andmed ning üleandmise viis ja kuupäev. Väljastatud andmeid hoitakse TÜ Teaduspilves, mis on läbinud ISKE auditi 2017. a detsembris ja vastab ISKE M taseme nõuetele (turvaklass T1K1S2). Ligipääs väljastatud andmetele on ainult taotluses nimetatud uurijatel ja uuringu kaastöötajatele, keda on informeeritud kohalduvatest andmekaitsenõuetest. Projektiga seotud algandmeid säilitatakse TÜ Teaduspilves alates publitseerimisest 15 aastat. Projekti käigus tekkivad uued andmed (uued geneetilised riskiskoorid depressiooni, Alzheimeri tõve ning kardiovaskulaarsete haiguste kohta) kantakse andmestiku rikastamise eesmärgil EGV andmebaasi ning säilitatakse tähtajatult (tulenevalt IGUS §18). Uurimistöö teostaja kohustused andmete töötlemisel Uurimistöö läbiviija on kohustatud järgima kõiki seadusest tulenevaid ja väljastamise korralduses toodud andmekaitse põhimõtteid. Uurimistöö teostaja kasutab andmeid ainult uurimistöö eesmärkidel ja ulatuses. Uurimistöö teostaja garanteerib andmete konfidentsiaalsuse. Peale uuringu lõppu andmete käitlemisele kohalduvad nõuded on sätestatud andmete väljastamise korralduses (nt ligipääsude tõkestamine, andmete hävitamine). Käesoleva taotluse on läbi vaadanud ja heaks kiitnud Tartu Ülikooli andmekaitse peaspetsialisti poolt volitatud isikud, kelleks on Eesti geenivaramu andmekogumise osakonna juhataja ja projektijuht Helene Alavere ning analüütik Evelin Tali. 1 1 . TEAVE SAMA PROJEKTI VARASEMATEST VÕI SAMAAEGSETEST HINDAMISTEST VÕI KOOSKÕLASTAMISTEST MUJAL Selle projekti raames kasutatakse mitmeid andmestikke teistest riikidest ja nende kasutamiseks on saadud järgnevad load välismaistelt eetikakomiteedelt : UK Biobank : UK Biobank taotluse number 22224, Stockholmi Regionaalse Eetikanõukogu luba number: 2017/2348-32 Rootsi kaksikuteregister : Stockholmi Regionaalse Eetikanõukogu luba number: 2017/2348-32 Health and Retirement Study : Stockholmi Regionaalse Eetikanõukogu luba number: 2015/1729-31/5 ( parandus 2019-02588) 1 2 . LISAD: 1 2 .1 Uuringu läbiviija(te) CV(d) Kasutatud kirjandus: ADDIN ZOTERO_BIBL {"uncited":[],"omitted":[],"custom":[]} CSL_BIBLIOGRAPHY 1. Singh-Manoux, A. et al. Trajectories of Depressive Symptoms Before Diagnosis of Dementia: A 28-Year Follow-up Study. JAMA Psychiatry 74 , 712–718 (2017). 2. Banerjee, S. et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet Lond. Engl. 378 , 403–411 (2011). 3. Dudas, R., Malouf, R., McCleery, J. & Dening, T. Antidepressants for treating depression in dementia. Cochrane Database Syst. Rev. (2018) doi:10.1002/14651858.CD003944.pub2. 4. Alexopoulos, G. S. et al. Cognitive control, reward-related decision making and outcomes of late-life depression treated with an antidepressant. Psychol. Med. 45 , 3111–3120 (2015). 5. Saczynski, J. S. et al. Antidepressant Use and Cognitive Decline: The Health and Retirement Study. Am. J. Med. 128 , 739–746 (2015). 6. Richardson, K. et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ 361 , k1315 (2018). 7. Heser, K. et al. Potentially inappropriate medication: Association between the use of antidepressant drugs and the subsequent risk for dementia. J. Affect. Disord. 226 , 28–35 (2018). 8. Lee, C. W., Lin, C. L., Sung, F. C., Liang, J. A. & Kao, C. H. Antidepressant treatment and risk of dementia: a population-based, retrospective case-control study. J. Clin. Psychiatry 77 , 117–22; quiz 122 (2016). 9. Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of polygenic risk scores. Nat. Rev. Genet. 19 , 581 (2018). 10. Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50 , 1219 (2018). 11. Lewis, C. M. & Hagenaars, S. P. Progressing Polygenic Medicine in Psychiatry Through Electronic Health Records. JAMA Psychiatry (2019) doi:10.1001/jamapsychiatry.2018.3975. 12. Lu, Y. et al. Genetic risk scores and family history as predictors of schizophrenia in Nordic registers. Psychol. Med. 48 , 1201–1208 (2018). 13. Wray, N. R. et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat. Genet. 50 , 668 (2018). 14. Desikan, R. S. et al. Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. PLoS Med. 14 , e1002258 (2017). Kaaskiri Eesti b ioeetika ja i nimuuringute n õukogule projekti “Individuaalsete geeniandmete rakendamine depressiooni ja dementsuse diagnostikas vanemaealistel” eetikaloale täiendava kaastöötaja lisamiseks Soovin lisada projekti “Individuaalsete geeniandmete rakendamine depressiooni ja dementsuse diagnostikas vanemaealistel” eetikaloale täiendava kaastöötaja Triinu Ojalo, kes on Tartu Ülikooli psühholoogia instituudi magistrant ning alustab oma magistritöö raames tööd käesoleva projekti juures. Uurimistööle on eelnevalt saadud EBIN kooskülastus 14. aprill 2020 nr 1.1-12/662. T riinu Ojalo magistritöö teema on „ Antidepressantide tarvitamine kõrge Alzheimeri tõve riskiga indiviididel Eesti geenivaramu valimil “ ning tema ülesanneteks on kirjanduse ülevaate koostamine antidepressantide kasutamisest dementsuse riski ja diagnoosiga indiviididel , geenivaramu andmete ettevalmistamine analüüsiks, andmeanalüüs, tulemuste tõlgendamine ning tehtud tööst magistritöö kirjutamine. Andmed tehakse talle kättesaadavaks kuni magistritöö kaitsmiseni (eeldatav aeg juuni 2021) või kuni kaheks aastaks ( august 2022). Magistrandi juhendaja olen mina, Kelli Lehto. Magistrant kasutab talle kättesaadavaks tehtud andmeid ainult projekti eesmärkide täitmiseks ja magistritöö kirjutamiseks . Ligipääs antakse põhitaotluses nimetatud pseudonüümitud andmetele , seega uusi andmeid geenivaramust ei väljastata. Magistrant kasutab andmetöötluseks parooliga turvatud tööarvutit, kust andmed kustutatakse pärast eelpool mainitud tähtaega. Triinu Ojaloga sõlmitakse konfidentsiaalsusleping pärast EBIN kooskõlastuse saamist ja enne projekti ülesannete täitmise alustamist. Täiendus on lisatud põhitaotlusele ja eristuvalt välja toodud. Ees- ja perekonnanimi: Triinu Ojalo Teaduslik kraad: BA psühholoogia Amet: TÜ psühholoogia instituudi magistrant Juhendaja: Kelli Lehto Töökoht: Genoomika instituut, Tartu Ülikool Töökoha aadress: Riia 23b e-post: [email protected] Allkiri: /allkirjastatud digitaalselt/ Kelli Lehto, PhD Neuropsühhiaatrilise geneetika vanemteadur Genoomika instituut Tartu Ülikool Teadur Krooniliste haiguste osakond Tervise Arengu Instituut /allkirjastatud digitaalselt/ CURRICULUM VITAE ISIKLIK INFORMATSIOON Nimi Triinu Ojalo Sünniaeg 31.12. 1979 Aadress Pärnu maantee 361, Tallinn 10919 Telefon 56 917 216 E-mail [email protected] HARIDUSKÄIK 2019- Tartu ülikool, psühholoogia magistritõpe 2016-2019 Tallinna Ülikool, psühholoogia bakalaureuseõpe Bakalaureusetöö: „Akadeemilise minakäsitluse, läbipõlemise ja õpetaja emotsionaalse toetuse seosed matemaatikasooritusega“ 1998-2004 Tartu Ülikool, bakalaureuseõpe (magistrikraadiga võrdsustatud) eesti filoloogia 1995-1998 Tallinna Ühisgümnaasium 1986-1995 Tallinna Kivimäe Põhikool PSÜHHOLOOGIA ALANE TÄIENDKOOLITUS 2017 KKT baaskoolitus (EKKA) TÖÖKOGEMUS 2016- vabakutseline tõlkija 2018-2019 Psühhiaatria ja psühhoteraapia keskus Sensus, assistent 2007-2016 Endla Teater – dramaturg, kunstilise juhi KT 2013-2015 Pärnu Sütevaka Humanitaargümnaasium – teatriloo õpetaja 2011-2013 Rahvusvaheline monoteatri festival Monomaffia – turundus- ja meediajuht 2003-2007 AS Tallink Silja – koolitusassistent KEELTEOSKUS Eesti emakeel Inglise väga hea kõnes ja kirjas Soome väga hea kõnes ja kirjas Vene kõnes rahuldav, kirjas nõrk Norra kõnes nõrk, kirjas rahuldav ARVUTIOSKUS Spetsialisti tase MS Office (Word, Excel, Powerpoint, Access), Adobe Pro DC Algtase SPSS, Adobe Photoshop
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel